Novacyt Akcie

Novacyt EPS

Zisk na akcii (EPS) společnosti Novacyt (ALNOV.PA) k datu 10. 8. 2026 je -0,59 GBP. V předchozím roce byl Zisk na akcii (EPS) -0,40 GBP — změna o 47,60 % (nižší).

EPS

-0,59GBP

YoY

47,60%

Poslední aktualizace:

Zisk na akcii (EPS) společnosti Novacyt je 2026 -0,59 GBP. Zisk na akcii (EPS) společnosti Novacyt byl 2025 -0,40 GBP. Klesá tak o 47,60% nižší než v předchozím roce.
Access this data via the Eulerpool API

Novacyt Analýza akcií

Co dělá Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií Novacyt

Zisk na akcii (EPS) společnosti Novacyt činí -0,59 GBP v roce 2026.

Zisk na akcii (EPS) společnosti Novacyt se změnilo z -0,40 GBP na -0,59 GBP, což představuje změnu o 47,60 %. Hodnota je nižší než v předchozím roce.

Na Eulerpool najdete úplný historický vývoj Zisk na akcii (EPS) Novacyt od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Zisk na akcii měří část zisku společnosti připadající na každou vydanou akcii a je klíčovou metrikou pro hodnocení ziskovosti společnosti na základě akcie.

EPS = Čistý zisk / Počet vydaných akcií

Access this data via the Eulerpool API

Výkaz zisku a ztráty — Novacyt

Všechny klíčové ukazatele — Novacyt